News
HSTOQ
0.0003
NaN%
--
Weekly Report: what happened at HSTOQ last week (1229-0102)?
Weekly Report · 01/05 10:20
Weekly Report: what happened at HSTOQ last week (1222-1226)?
Weekly Report · 12/29/2025 10:20
Weekly Report: what happened at HSTOQ last week (1215-1219)?
Weekly Report · 12/22/2025 10:19
Weekly Report: what happened at HSTOQ last week (1208-1212)?
Weekly Report · 12/15/2025 10:27
Weekly Report: what happened at HSTOQ last week (1201-1205)?
Weekly Report · 12/08/2025 10:25
Weekly Report: what happened at HSTOQ last week (1124-1128)?
Weekly Report · 12/01/2025 10:21
Weekly Report: what happened at HSTOQ last week (1117-1121)?
Weekly Report · 11/24/2025 10:26
Weekly Report: what happened at HSTOQ last week (1110-1114)?
Weekly Report · 11/17/2025 10:26
Weekly Report: what happened at HSTOQ last week (1103-1107)?
Weekly Report · 11/10/2025 10:23
Weekly Report: what happened at HSTOQ last week (1027-1031)?
Weekly Report · 11/03/2025 10:24
Weekly Report: what happened at HSTOQ last week (1020-1024)?
Weekly Report · 10/27/2025 10:27
Weekly Report: what happened at HSTOQ last week (1013-1017)?
Weekly Report · 10/20/2025 10:23
Weekly Report: what happened at HSTOQ last week (1006-1010)?
Weekly Report · 10/13/2025 10:26
Weekly Report: what happened at HSTOQ last week (0929-1003)?
Weekly Report · 10/06/2025 10:22
Weekly Report: what happened at HSTOQ last week (0922-0926)?
Weekly Report · 09/29/2025 10:24
Weekly Report: what happened at HSTOQ last week (0915-0919)?
Weekly Report · 09/22/2025 10:24
Weekly Report: what happened at HSTOQ last week (0908-0912)?
Weekly Report · 09/15/2025 11:29
More
Webull provides a variety of real-time HSTOQ stock news. You can receive the latest news about Histogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About HSTOQ
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.